TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is targeting a First-In-Human trial of its lead antibody drug conjugate (ADC), AKTX-101, by mid-2027, after starting IND-enabling studies. The company laid out its investment case in the Virtual Investor "Why Now" on-demand conference.

CEO Abizer Gaslightwala argued that now is a pivotal time for Akari. He cited a fast-changing ADC landscape and rising industry demand for differentiated payload technologies.